Biohaven Ltd

Common Name
Biohaven
Country
United States
Sector
Healthcare
Industry
Biotechnology
Employees
256
Ticker
BHVN
Exchange
NEW YORK STOCK EXCHANGE, INC.
Description
Biohaven Ltd. is a clinical-stage biopharmaceutical company that focuses on creating novel therapies for neurological and neuropsychiatric diseases. Its primary function is to develop innovative drugs...

Biohaven's Financial Statements Preview

Below are the financial statements of Biohaven, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

Interested in getting early access to our real-time standardized financial datafeed?
Learn More
All figures in millions of USD
2024
2023
2022
Operating expenses
Research and development
-795.87a
-373.28a
-437.07a
General and administrative
-89.24a
-62.77a
-130.86a
Total operating expenses
-885.11a
-436.05a
-567.93a
Loss from operations
-885.11a
-436.05a
-567.93a
Other income (expense)
Other income (expense), net
39.42a
26.5a
-1.91a
Total other income (expense), net
39.42a
26.5a
-1.91a
Loss before provision (benefit) for income taxes
-845.69a
-409.55a
-569.84a
Provision (benefit) for income taxes
-0.74a
-1.38a
-0.44a
Net loss
-846.42a
-408.17a
-570.28a
Download Data

Verified Sources Behind Biohaven’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Biohaven’s data sources below and access millions more through our Disclosure Search.

a. Biohaven's 10-K 2024
a. Biohaven's 10-K 2024
Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

Tracenable is building real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?